Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Given Imaging's Capsule Endoscope to Be Reimbursed at \77,200
October 15, 2007
- World's First Recombinant Serum Albumin Recommended for Approval
October 15, 2007
- Takara Bio Licenses LA-PCR Technology to Kapa Biosystems
October 15, 2007
- Genzyme's Elaprase Receives Ultra-early Approval
October 15, 2007
- MEDICAL DEVICE NEWS IN BRIEF
October 15, 2007
- Approval of Concerta for ADHD Withheld
October 15, 2007
- Inhibition of Both Absorption and Production of LDL-C Important: Schering-Plough
October 15, 2007
- Argatroban Applied for HIT Based on Results of Physician-Initiated Trial
October 15, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 15, 2007
- REGULATORY NEWS IN BRIEF
October 15, 2007
- SELF-MEDICATION NEWS IN BRIEF
October 15, 2007
- COMMENTARY／FPMAJ's Drug Pricing System Reform Proposal Meets with Objection
October 15, 2007
- MEDICAL DEVICE NEWS IN BRIEF
October 8, 2007
- Banyu Mounts Sales Drive for Once-Weekly Fosamac
October 8, 2007
- New Vision for Medical Device Industry to Call For Fusion of Drugs and Devices
October 8, 2007
- NEW PRODUCTS／GSK, Taisho to Launch Japan's First OTC Drug for Labial Herpes
October 8, 2007
- GENERICS NEWS IN BRIEF
October 8, 2007
- DBV Tech. to Enter Japanese Market with Viaskin Technology
October 8, 2007
- R&D NEWS IN BRIEF
October 8, 2007
- NEW PRODUCTS／Kyowa Hakko Kogyo: Topina Tablets for Partial Seizures
October 8, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…